Europlasma Financials
| ALEUP Stock | EUR 0.1 0.03 20.83% |
Europlasma |
Understanding current and past Europlasma Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Europlasma's financial statements are interrelated, with each one affecting the others. For example, an increase in Europlasma's assets may result in an increase in income on the income statement.
Europlasma Stock Summary
Europlasma competes with Gaussin. Europlasma S.A., together with its subsidiaries, engages in plasma solutions, renewable energies, and asbestos waste treatment activities in France. Europlasma S.A. was founded in 1992 and is based in Pessac, France. EUROPLASMA operates under Waste Management classification in France and is traded on Paris Stock Exchange. It employs 116 people.| Instrument | France Stock View All |
| Exchange | Euronext Paris |
| ISIN | FR0013514114 |
| Business Address | 3-5 AllEe des |
| Sector | Commercial Services & Supplies |
| Industry | Industrials |
| Benchmark | Dow Jones Industrial |
| Website | www.europlasma.com |
| Phone | 33 5 56 49 70 00 |
| Currency | EUR - Euro |
You should never invest in Europlasma without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Europlasma Stock, because this is throwing your money away. Analyzing the key information contained in Europlasma's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Europlasma Key Financial Ratios
Europlasma's financial ratios allow both analysts and investors to convert raw data from Europlasma's financial statements into concise, actionable information that can be used to evaluate the performance of Europlasma over time and compare it to other companies across industries.Europlasma Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Europlasma's current stock value. Our valuation model uses many indicators to compare Europlasma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Europlasma competition to find correlations between indicators driving Europlasma's intrinsic value. More Info.Europlasma SA is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Europlasma's earnings, one of the primary drivers of an investment's value.Europlasma SA Systematic Risk
Europlasma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Europlasma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Europlasma SA correlated with the market. If Beta is less than 0 Europlasma generally moves in the opposite direction as compared to the market. If Europlasma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Europlasma SA is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Europlasma is generally in the same direction as the market. If Beta > 1 Europlasma moves generally in the same direction as, but more than the movement of the benchmark.
Europlasma December 1, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Europlasma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Europlasma SA. We use our internally-developed statistical techniques to arrive at the intrinsic value of Europlasma SA based on widely used predictive technical indicators. In general, we focus on analyzing Europlasma Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Europlasma's daily price indicators and compare them against related drivers.
| Downside Deviation | 9.2 | |||
| Information Ratio | 0.0017 | |||
| Maximum Drawdown | 96.67 | |||
| Value At Risk | (10.07) | |||
| Potential Upside | 6.67 |
Additional Tools for Europlasma Stock Analysis
When running Europlasma's price analysis, check to measure Europlasma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Europlasma is operating at the current time. Most of Europlasma's value examination focuses on studying past and present price action to predict the probability of Europlasma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Europlasma's price. Additionally, you may evaluate how the addition of Europlasma to your portfolios can decrease your overall portfolio volatility.